Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Financials
52W LOW $18.8252W HIGH $40.79
Volume
8.52 M
Value Traded
200.08 M
Short % Float
2.84%
+5.06%Week
+12.7%1 Month
+26.04%3 Month
+34.75%6 Month
+215.46%5 Year
+5,163.2%All Time
Cash Data
- Cash FlowProfitable
- SEC Filing
Key Stats
Market Cap
48.47 B
EPS (TTM)
0.61
P/E Ratio
68.51
Ent. Value
49.42 B
Total Shares
1.17 B
Float Shares
1.11 B
Insiders
4.90%
Institutions
23.04%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
TEVA Catalyst Timeline
Dated clinical, regulatory and corporate events for Teva Pharmaceutical Industries Limited
Catalyst Timeline
Dated clinical, regulatory & corporate events for Teva Pharmaceutical Industries Limited
135Total events
6Upcoming
48Tier-1 (high impact)
2016 to 2026Coverage
Upcoming catalysts 2
Event history 50
●Oral PresentationecopipamFiledPresentation
New ecopipam efficacy and safety data presented at MDS Congress in Seoul
pediatric patients with Tourette syndromesource ↗
▲Subgroup AnalysisecopipamFiledClinical Data
Post hoc analysis: co-occurring psychiatric conditions did not impact ecopipam efficacy or safety
Tourette syndrome with co-occurring psychiatric conditionssource ↗
▲Interim AnalysisecopipamFiledTrial
Interim 18-month OLE analysis: 45.6% mean reduction in tic severity, no new safety signals
Tourette syndromesource ↗
▲Topline ReadoutecopipamFiledClinical Data
Post hoc pooled analysis: ~70% clinically meaningful tic reduction within 8 weeks
Tourette syndromesource ↗
●Preclinical PoCecopipamFiledPreclinical
Preclinical receptor selectivity findings for ecopipam presented at MDS
Tourette syndromesource ↗
●PublicationecopipamFiledPresentation
Journal of Child Neurology publishes review on dopamine pathways and ecopipam in Tourette syndrome
Tourette syndrome in pediatric patientssource ↗
▲Partnership / LicenseCorporate
Samsung Bioepis and Teva enter global license, development and commercialization agreement for up to six potential biosimilar candidates
▲FDA ApprovalDEGEVMAApprovedFDA Decision
FDA approves DEGEVMA (denosumab-adet), a biosimilar to Xgeva
prevention of bone complications in adults with advanced cancer that has spread to the bone; giant cell tumor of bone; hypercalcemia of malignancysource ↗
▲Topline ReadoutecopipamFiledClinical Data
D1AMOND Phase 3 ecopipam trial results in Tourette syndrome
Tourette syndromesource ↗
▲FDA ApprovalPONLIMSIApprovedFDA Decision
FDA approved PONLIMSI (denosumab-adet) in March 2026
indications of Prolia (denosumab)source ↗
▲Full ResultsecopipamFiledClinical Data
Phase 3 ecopipam Tourette syndrome results published in JAMA Neurology
Tourette syndromesource ↗
▲EU ApprovalDEGEVMAApprovedEx-US Regulatory
DEGEVMA approved in the European Union
biosimilar to Xgeva (denosumab)source ↗
▲Long Term DataecopipamFiledClinical Data
12-month open-label extension data for ecopipam in pediatric Tourette syndrome published
Tourette syndromesource ↗
▲PublicationecopipamFiledPresentation
12-month ecopipam open-label safety data published in Movement Disorders Clinical Practice
Tourette syndrome in pediatric patientssource ↗
▲Long Term DataecopipamFiledClinical Data
12-month open-label extension shows sustained tic severity reductions with ecopipam
Tourette syndrome in pediatric patientssource ↗
▲Primary Endpoint MetClinical Data
Positive Phase 3 efficacy results for olanzapine Once-Monthly LAI
schizophreniasource ↗
◆Timing GuidancePresentation
Initial program results expected in 2024
Ulcerative Colitis and Crohn's Diseasesource ↗
▲Product LaunchNarcanPost-Market
Expansion of generic Narcan shipments expected under nationwide settlement
opioid overdosesource ↗
▲Codev CocommercialCorporate
Sanofi and Teva announce exclusive collaboration to co-develop and co-commercialize TEV 574
Ulcerative Colitis and Crohn's Diseasesource ↗
▲Drug Safety CommunicationSafety
Deferred prosecution agreement with DOJ to settle criminal price-fixing charges
▲Product LaunchNarcanPost-Market
Shipments of generic Narcan began under prior opioid settlements
opioid overdosesource ↗
▲FDA ApprovalUZEDYApprovedFDA Decision
FDA approval of UZEDY (risperidone) extended-release injectable suspension
schizophreniasource ↗
▲Product LaunchPost-Market
Launch of additional strengths (2.5 mg and 20 mg) for lenalidomide capsules in the U.S.
▲FDA ApprovalFDA Decision
FDA approval of AUSTEDO XR (deutetrabenazine) extended-release tablets
tardive dyskinesia and chorea associated with Huntington's diseasesource ↗
▲Full ResultsecopipamFiledClinical Data
Phase 2b D1AMOND trial results for ecopipam in pediatric Tourette syndrome published in Pediatrics
Tourette syndromesource ↗
▲PublicationecopipamFiledPresentation
Phase 2b ecopipam Tourette syndrome randomized trial published in Pediatrics
Tourette syndrome in pediatric patientssource ↗
◆Management ChangeCorporate
Richard Francis appointed President and CEO effective January 1, 2023
▲Full ResultsecopipamFiledClinical Data
Phase 2b ecopipam Tourette syndrome trial published in Pediatrics
Tourette syndromesource ↗
▲Product LaunchPost-Market
Launch of first generic version of Revlimid (lenalidomide capsules) in the United States
multiple myeloma, myelodysplastic syndromessource ↗
Past FDA Catalysts and PDUFA Decisions
How TEVA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-09 | TEV-'749 (subcutaneous olanzapine LAI; TV-44749) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
A85 / 100
Pipeline Score
$48.0B
Pipeline Value
$66.5B
Commercial Value
Undervalued
Valuation Signal
84
Drugs Scored
3.5x
rNPV / MCap
Top 1%
Mid Cap(rank 8 of 658)
Percentile Rank
Teva Pharmaceutical Industries Limited earns an A-grade pipeline score (85/100), with $56.5B risk-adjusted pipeline value, led by Budesonide/Formoterol SPIROMAX in Asthma (Phase 3).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $17.3B x 3.8 = $66.5B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Austedo | $2.6B | $1.9B | +39.5% |
| Ajovy | $819M | $573M | +42.9% |
| COPAXONE | $469M | $482M | -2.7% |
| UZEDY | $238M | $170M | +40% |
| BENDEKA and TREANDA | $126M | $157M | -19.7% |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| TEV-56248 Small moleculeNCT06290102 | Asthma | Phase 3 | COMPLETED | 3,454 | Oct 7, 2024 |
Clinical Trial Results
Readouts, endpoints and source filings for every TEVA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ecopipam PriorityFast TrackOrphan | Tourette syndrome | Phase 3 | 2026-10-02 | continued ecopipam treatment cut the risk of tic relapse by 50% versus placebo in pediatric participants (HR: 0.5; P=0.008)Read More | Journal of Child Neurology Publishes Review Highlighting Dopamine’s Role in Tourette Syndrome and Ecopipam’s Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric PatientsRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| MIGNONE ROBERTODirector | Sell | -367,600 | $39.06 | 09/18/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in TEVA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TRI LOCUM PARTNERS LP | 3.1 % (-27.9 %) | 25.30 M | 746.84 K | -26.85% ( -274.17 K) |
TEVA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-30 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How TEVA ranks across every disease it competes in
Competitive Position is a premium feature
See how TEVA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialTEVA News
TEVA▲ +6%today
Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia
Teva Pharmaceuticals has received FDA approval for WELTRUZA (olanzapine), a once-monthly subcutaneous injectable for treating schizophrenia in adults. This innovative formulation requires no loading doses or oral supplementation and has shown significant symptom improvement in clinical trials. WELTRUZA aims to enhance adherence and reduce relapse rates among patients. It will be available in three strengths soon.
Read more →TEVAJournal of Child Neurology Publishes Review Highlighting Dopamine’s Role in Tourette Syndrome and Ecopipam’s Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients
Teva Pharmaceuticals announced a review published in the Journal of Child Neurology, discussing dopamine's role in Tourette syndrome and the potential of ecopipam, a selective D1 receptor antagonist. The review suggests that ecopipam may effectively reduce tic severity in pediatric patients while avoiding common side effects associated with traditional antipsychotics. Clinical trial data supports its efficacy and tolerability, highlighting its innovative approach to treatment.
Read more →TEVATeva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome
Teva Pharmaceuticals presented new efficacy and safety data for ecopipam, an investigational treatment for pediatric Tourette syndrome, at the International Congress of Parkinson’s Disease and Movement Disorders. The data revealed that approximately 70% of participants experienced clinically meaningful tic reduction within 8 weeks. An interim analysis also indicated a sustained reduction in tic severity over 18 months without new safety concerns.
Read more →TEVASamsung Bioepis and Teva Expand Strategic Partnership to Advance Up to Six Potential Biosimilar Candidates
Samsung Bioepis and Teva have expanded their strategic partnership to include the development of up to six potential biosimilar candidates. The agreement specifically mentions SB41 and SB44, referencing Fasenra and Ilaris, respectively. This collaboration aims to leverage Samsung's development and manufacturing strengths alongside Teva's global commercialization capabilities, enhancing access to biosimilars in key markets.
Read more →TEVATAPI (Technology & API Services) Names Serge Rogasik CEO to lead next chapter of growth and competitiveness
TAPI has appointed Serge Rogasik as its new CEO to lead the company into its next growth phase. Rogasik, with over 25 years of experience, aims to leverage TAPI's extensive capabilities in active pharmaceutical ingredients and contract development and manufacturing. The company is positioned to support the pharmaceutical industry's focus on supply chain resilience and geographic diversification. TAPI will showcase its offerings at CPHI Milan in October 2026.
Read more →TEVATeva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)
Teva Pharmaceutical Industries has received FDA approval for DEGEVMA™ (denosumab-adet), a biosimilar to Xgeva® (denosumab). This approval covers all indications of the reference product, including preventing bone complications in advanced cancer patients. DEGEVMA is Teva's second FDA-approved biosimilar in 2026, enhancing its denosumab portfolio and supporting its growth strategy.
Read more →TEVATeva Releases Q3 2026 Aide Memoire
Teva Pharmaceutical Industries Ltd. announced the availability of its Q3 2026 Aide Memoire, which compiles public information to assist investors ahead of the upcoming quarterly results. The results are expected to be released on November 3, 2026, followed by a conference call. The document outlines management's previous commentary and includes forward-looking statements that highlight potential risks.
Read more →TEVATeva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET
Teva Pharmaceutical Industries Ltd. will release its third quarter 2026 financial results on November 3, 2026, at 7:00 a.m. ET. A conference call and live webcast will follow at 8:00 a.m. ET. Participants must register in advance to join the call. A replay will be available on Teva's website within 24 hours post-call.
Read more →TEVANew Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients
Teva Pharmaceuticals presented new data at Psych Congress detailing healthcare providers' preferences for treating tardive dyskinesia (TD) in older patients. Key attributes influencing treatment decisions include drowsiness risk and long-term efficacy. AUSTEDO emerged as the preferred VMAT2 inhibitor, aligning with provider priorities. The findings underscore the need for effective TD management.
Read more →TEVATeva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs
Teva Pharmaceuticals announced new real-world data demonstrating that UZEDY (risperidone) significantly outperforms other long-acting injectables for schizophrenia and bipolar I disorder. The findings indicate that UZEDY enhances treatment adherence, reduces emergency care visits, and lowers healthcare costs, with an average savings of over $1,000 per patient per month. These results were presented at Psych Congress 2026.
Read more →TEVATeva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults
Teva Pharmaceuticals presented new post hoc data on TEV-'749, a once-monthly injectable formulation of olanzapine for schizophrenia, highlighting its efficacy and safety from the Phase 3 SOLARIS trial. Over half of participants achieved stabilization, with low relapse rates. The findings support the potential of TEV-'749 as a treatment option for patients switching from daily oral olanzapine.
Read more →TEVATeva Launches LongActingImpact.com to Advance Understanding of Earlier, Effective and Uninterrupted Schizophrenia Care
Teva Pharmaceuticals has launched LongActingImpact.com, a new educational resource aimed at healthcare providers to facilitate informed discussions about long-acting injectables (LAIs) for schizophrenia care. The site offers guidance on the benefits of LAIs, strategies for improving medication adherence, and support for continuity of care. This initiative addresses the challenges of treatment adherence, which affects a significant portion of patients with schizophrenia.
Read more →TEVATeva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy
Teva Pharmaceutical Industries Ltd. has commenced trading its ordinary shares directly on the NYSE, marking a significant step in its Pivot to Growth strategy. This transition is expected to enhance investor access and reflects the company's financial strength, bolstered by recent investment-grade ratings. Teva aims to leverage its innovative medicines portfolio to drive sustainable growth and shareholder value.
Read more →TEVATeva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes
Teva Pharmaceutical Industries Ltd. has successfully priced approximately $4.9 billion in senior notes. The proceeds will be utilized for conditional redemptions of existing notes and general corporate purposes. The settlement is anticipated around September 16, 2026, subject to customary closing conditions. Teva's financial strategy aims to enhance its capital structure while managing existing debt.
Read more →TEVATeva Announces Launch of Offering of Senior Notes
Teva Pharmaceutical Industries Ltd. has announced its intention to issue senior notes through its finance subsidiaries. The offering includes both EUR and USD-denominated notes, with proceeds aimed at funding redemptions of existing notes and other corporate purposes. The offering is contingent on market conditions, highlighting potential risks in execution.
Read more →TEVATeva to Present at the Goldman Sachs Global Healthcare Conference
Teva Pharmaceutical Industries Ltd. announced that CEO Richard Francis will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on June 8, 2026. The event will be accessible via live webcast on Teva's Investor Relations website. Archived versions will be available for 30 days post-event.
Read more →TEVATeva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution
Teva Pharmaceutical Industries Ltd. reported Q1 2026 revenues of approximately $4.0 billion, marking a 2% increase year-over-year in U.S. dollars. The growth was primarily driven by innovative products like AUSTEDO and AJOVY, despite a decline in generics revenue due to competition. Teva's Pivot to Growth strategy is on track, with an optimistic outlook for the year ahead, including an acquisition of Emalex Biosciences.
Read more →TEVATeva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy
Teva Pharmaceuticals has announced its acquisition of Emalex Biosciences, which includes ecopipam, a first-in-class therapy for pediatric Tourette syndrome. The acquisition, valued at $700 million with potential additional payments, aims to enhance Teva's neuroscience pipeline and address significant unmet medical needs. The NDA submission for ecopipam is expected in the second half of 2026, pending regulatory approval.
Read more →TEVATeva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)
Teva has received U.S. FDA approval for its biosimilar PONLIMSI™ (denosumab-adet) and the acceptance of a dual filing for its biosimilar candidate to Xolair® (omalizumab), indicating a positive development in its biosimilar portfolio.
Read more →TEVATeva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026
Teva Pharmaceutical Industries Ltd. will announce its first quarter 2026 financial results on April 29, 2026, at 7:00 a.m. ET. A conference call and live webcast will follow at 8:00 a.m. ET. Participants must register in advance to obtain access details. The webcast will be available for replay within 24 hours after the call.
Read more →About Teva Pharmaceutical Industries Limited
HeadquartersTEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV
BIOPHARMAWATCH ELITE PLUS
Trade the next TEVA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime